Lymphocyte subpopulations in peripheral blood of breast cancer patients

Abstract

s / The Breast 20 (2011) S12–S55 S25 Results: Similarly, association between p53 protein and disease response was evaluated. With 90% confidence it was established, that p53 protein overexpression influences disease progression (Fisher‘s p 1⁄4 0.096). Wealso estimated the impactof proteinexpressionondisease outcomes in 24 patients who underwent only first-line treatment against metastatic breast cancer. If p53 protein overexpression was found, mean survival was 28.5 months (SEM1⁄4 5.4, 95% CI 17.9–39.0) andmedian 25months (SEM1⁄4 6.9, 95% CI 11.4–38.6), if itwasabsent– survivalwas slightly longer:mean33.6months (SEM1⁄4 4.2, 95%CI 25.3–41.8) andmedian 30months (SEM1⁄4 2.6, 95%CI 24.9– 35.0). Kaplan-Meiermethod did not detect statistically significant differences between the groups (log-rank p > 0.05, Breslow p > 0.05). For small samples, associations among molecular markers were evaluated using Fisher‘s exact test. It was established, that p53 protein has a trend to be associated with underexpression of ER (OR1⁄4 5.83, 95% CI 0.9–37.81, p1⁄4 0.064). Associations among other factors were non-significant. Analysis of combinations of ER and PR (ER-PR-, ER-PR+, ER+PR-, ER+PR+) with p53 protein and HER2 was also conducted. However, there were no significant association between them. Additionally, combination of negative expression in 3 markers (ER, PR and HER2) with p53 protein expressionwas checked. Thus, significant associationwas found between positive p53 protein expression and combination of molecular markers ER-PRHER2(Fisher‘s p 1⁄4 0.041). Conclusion: It was established, that combination of molecular markers ER-PR-HER2is 7.7 times (95% CI 1.16–51.17; p 1⁄4 0.035) more likely in case of positive expression of p53 protein and it is associated with the worse prognosis of the patients.